| scholarly article | Q13442814 |
| P50 | author | Masaki Muramatsu | Q80917845 |
| P2093 | author name string | Carmelo Puliatti | |
| Roberto Cacciola | |||
| Atsushi Aikawa | |||
| Magdi M Yaqoob | |||
| Hector Daniel Gonzalez | |||
| P2860 | cites work | A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee | Q83175109 |
| Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation | Q83330294 | ||
| Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience | Q83396331 | ||
| ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption | Q83552932 | ||
| Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression | Q83748536 | ||
| Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation | Q84507494 | ||
| ABO-incompatible kidney transplantation in children | Q84575553 | ||
| ABO-incompatible kidney transplantation | Q84820579 | ||
| Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B? | Q85044999 | ||
| ABO incompatible kidney transplantation - an analysis of UNOS Registry data | Q31034921 | ||
| Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action | Q33370836 | ||
| Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma | Q33487992 | ||
| Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients | Q33560520 | ||
| ABO-incompatibility in solid organ transplantation | Q34352971 | ||
| Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin | Q34362734 | ||
| Payment for living donor (vendor) kidneys: a cost-effectiveness analysis | Q34649382 | ||
| Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications | Q35142598 | ||
| Experiences with renal homotransplantation in the human: report of nine cases | Q35279411 | ||
| Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. | Q35611406 | ||
| Outcomes of ABO-incompatible kidney transplantation in the United States | Q35822937 | ||
| Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation | Q35953320 | ||
| Intravenous immunoglobulin: adverse effects and safe administration | Q36359670 | ||
| The emerging role of rituximab in organ transplantation | Q36530278 | ||
| The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 | ||
| The role of ABO-incompatible living donors in kidney transplantation: state of the art. | Q36872442 | ||
| Antibody-mediated rejection in renal allografts: lessons from pathology | Q36910391 | ||
| Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients | Q36936436 | ||
| Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. | Q37064446 | ||
| Cancer risk after ABO-incompatible living-donor kidney transplantation | Q37138338 | ||
| Complications of splenectomy | Q37154229 | ||
| Managing cancer risk and decision making after kidney transplantation | Q37265181 | ||
| ABO incompatible renal transplantation: a paradigm ready for broad implementation | Q37454277 | ||
| Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. | Q37572815 | ||
| Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts | Q37573649 | ||
| Transplantation of discordant xenografts: a review of progress | Q37781951 | ||
| Kidney paired donation: fundamentals, limitations, and expansions | Q37823966 | ||
| Steroid avoidance in renal transplantation | Q37918294 | ||
| Current topics in therapeutic plasmapheresis | Q38124250 | ||
| Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation | Q38476939 | ||
| Risk factors for cancer in renal transplant recipients | Q39225008 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Side effects of high-dose intravenous immunoglobulins | Q41613277 | ||
| Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation--single center analysis | Q79651861 | ||
| Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation | Q79741109 | ||
| Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation | Q79897615 | ||
| Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation | Q79955710 | ||
| ABO-incompatible living donor transplantation: is it economically "compatible"? | Q79955721 | ||
| C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings | Q80061434 | ||
| Cancer after kidney transplantation in the United States | Q80096845 | ||
| Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan | Q80198398 | ||
| Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations | Q80318166 | ||
| Interinstitutional variation in the measurement of anti-A/B antibodies: the Japanese ABO-Incompatible Transplantation Committee survey | Q80418534 | ||
| Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers | Q80418535 | ||
| Present techniques for antibody removal | Q80418538 | ||
| Preemptive postoperative antigen-specific immunoadsorption in ABO-incompatible kidney transplantation: necessary or not? | Q80418541 | ||
| Predicting subsequent decline in kidney allograft function from early surveillance biopsies | Q81214502 | ||
| A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation | Q82055056 | ||
| Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period | Q82350692 | ||
| The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy | Q83175074 | ||
| RENAL HOMOGRAFTS IN PATIENTS WITH MAJOR DONOR-RECIPIENT BLOOD GROUP INCOMPATIBILITIES. | Q42382030 | ||
| Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis | Q43064220 | ||
| Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection | Q43222014 | ||
| ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab | Q43632100 | ||
| ABO-incompatible living-donor kidney transplantation in children | Q43752470 | ||
| ABO-incompatible kidney transplantation using both A2 and non-A2 living donors | Q44077744 | ||
| The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction | Q44135123 | ||
| Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis | Q44228631 | ||
| Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab | Q44329139 | ||
| Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury | Q44512119 | ||
| Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab | Q44584381 | ||
| Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy. | Q44632269 | ||
| ABO-incompatible pediatric kidney transplantation in a single-center trial | Q44895576 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls | Q45027158 | ||
| Duration of end-stage renal disease and kidney transplant outcome. | Q45245881 | ||
| Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors | Q46100656 | ||
| ABO incompatible living renal transplantation with a steroid sparing protocol. | Q46318507 | ||
| ABO blood type-incompatible kidney transplantation and access to organs | Q46355397 | ||
| ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies | Q46410666 | ||
| ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up | Q46518667 | ||
| Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression | Q46775141 | ||
| Double-filtration plasmapheresis | Q46830379 | ||
| Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. | Q47778948 | ||
| ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. | Q50579449 | ||
| Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. | Q50755303 | ||
| Cost-effectiveness analysis of renal replacement therapy in Austria. | Q51158730 | ||
| The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. | Q51738133 | ||
| Kidney paired donation and optimizing the use of live donor organs. | Q51975686 | ||
| The case for a living emotionally related international kidney donor exchange registry. | Q53424239 | ||
| Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. | Q53626859 | ||
| Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. | Q54481297 | ||
| Present experiences in a series of 26 ABO-incompatible living donor renal allografts. | Q55060639 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| Living-related and unrelated donor kidney transplantation: comparison between ABO-compatible and incompatible grafts | Q68120660 | ||
| Successful transplantation of blood group A2 kidneys into non-A recipients | Q68127610 | ||
| ABO blood group incompatibility in renal transplantation | Q69902747 | ||
| Adverse effects of intravenous immunoglobulin therapy | Q71577292 | ||
| Quantitative Measurments Concerning A and B Antigen Sites | Q72334724 | ||
| Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation | Q73212215 | ||
| Long-term results of ABO-incompatible living kidney transplantation: a single-center experience | Q74150549 | ||
| Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation | Q74265391 | ||
| Relation between ABO blood type antigen and antibody and acute vascular rejection in ABO incompatible kidney transplantation | Q77632800 | ||
| The economics of kidney transplantation versus hemodialysis | Q77709270 | ||
| Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis | Q78571279 | ||
| Multicentre trial of ABO-incompatible kidney transplantation. Japanese Biosynsorb ABO-incompatible kidney transplant study group | Q79311125 | ||
| Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation | Q79369493 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 18-29 | |
| P577 | publication date | 2014-03-24 | |
| P1433 | published in | World journal of transplantation | Q27725045 |
| P1476 | title | ABO incompatible renal transplants: Good or bad? | |
| P478 | volume | 4 |
| Q48841234 | A WHO reference reagent to standardize haemagglutination testing for anti-A and anti-B in serum and plasma: international collaborative study to evaluate a candidate preparation |
| Q45074583 | Broadened Allocation of Pancreas Transplants Across Compatible ABO Blood Types |
| Q36740471 | Comparison of clinical outcomes between ABO-compatible and ABO-incompatible spousal donor kidney transplantation |
| Q51278476 | Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report. |
| Q36400872 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: Experience of one center |
| Q41905860 | Fifteen-Year Analysis of Deceased Kidney Donation: A Single Transplant Center Experience in a Region of Northern Italy |
| Q92382408 | Identification of an activation-related protein in B cells in the ABO incompatible condition |
| Q38226323 | Increasing access to kidney transplantation in countries with limited resources: the Indian experience with kidney paired donation |
| Q39202644 | Initial experience with hand-assisted laparoscopic donor nephrectomy: a single-centre experience over 5 years. |
| Q35565364 | One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts |
| Q37088929 | Ongoing higher infection rate in ABO-incompatible kidney transplant recipient: is it a serious problem? A single-center experience |
| Q40245497 | Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study |
| Q47556851 | Polyoma virus nephropathy in kidney transplantation. |
| Q38645385 | Potential Roles for C1 Inhibitor in Transplantation |
| Q37170056 | Production of human blood group B antigen epitope conjugated protein in Escherichia coli and utilization of the adsorption blood group B antibody |
| Q38538684 | Renal transplantation in infants |
| Q33697397 | Successful Renal Transplantation Across HLA Barrier: Report from India |
| Q40670409 | The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. |
| Q37127991 | Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates |
Search more.